title: Outcome in cardiac recipients of donor hearts with increased left ventricular wall thickness.
abstract: The ongoing shortage of donors for cardiac transplantation has led to a trend toward acceptance of donor hearts with some structural abnormalities including left ventricular hypertrophy. To evaluate the outcome in recipients of donor hearts with increased left ventricular wall thickness (LVWT), we retrospectively analyzed data for 157 cardiac donors and respective recipients from January 2001 to December 2004. There were 47 recipients of donor heart with increased LVWT >or=1.2 cm, which constituted the study group and 110 recipients of a donor heart with normal LVWT < 1.2 cm that formed the control group. At 3 +/- 1.5 years, recipient survival was lower (50% vs. 82%, p = 0.0053) and incidence of allograft vasculopathy was higher (50% vs. 22%, p = 0.05) in recipients of donor heart with LVWT > 1.4 cm as compared to LVWT <or= 1.4 cm. By Cox regression, donor LVWT > 1.4 cm (p = 0.003), recipient preoperative ventricular assist device (VAD) support (p = 0.04) and bypass time > 150 min (p = 0.05) were predictors of reduced survival. Our results suggest careful consideration of donor hearts with echocardiographic evidence of increased LVWT in the absence of hypovolemia, because they may be associated with poorer outcomes; such hearts should potentially be reserved only for the most desperately ill recipients.
authors.affiliation: Department of Cardiac Transplant, Stanford University, Stanford, CA, USA. sumans@yahoo.com
authors.forename: S S
authors.initials: SS
authors.lastname: Kuppahally
authors.forename: H A
authors.initials: HA
authors.lastname: Valantine
authors.forename: D
authors.initials: D
authors.lastname: Weisshaar
authors.forename: H
authors.initials: H
authors.lastname: Parekh
authors.forename: Y Y
authors.initials: YY
authors.lastname: Hung
authors.forename: F
authors.initials: F
authors.lastname: Haddad
authors.forename: M
authors.initials: M
authors.lastname: Fowler
authors.forename: R
authors.initials: R
authors.lastname: Vagelos
authors.forename: M G
authors.initials: MG
authors.lastname: Perlroth
authors.forename: R C
authors.initials: RC
authors.lastname: Robbins
authors.forename: S A
authors.initials: SA
authors.lastname: Hunt
mesh_terms: D000328:Adult; D000959:Antihypertensive Agents / Q000627:therapeutic use; D001706:Biopsy; D017023:Coronary Angiography; D004452:Echocardiography; D005260:Female; D016027:Heart Transplantation / Q000276:immunology / Q000401:mortality / Q000473:pathology* / Q000502:physiology*; D006352:Heart Ventricles / Q000473:pathology*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009206:Myocardium / Q000473:pathology*; D018579:Patient Selection; D012189:Retrospective Studies; D016019:Survival Analysis; D014019:Tissue Donors / Q000706:statistics & numerical data* / Q000600:supply & distribution; D020858:Tissue and Organ Harvesting / Q000379:methods; D016896:Treatment Outcome; D018487:Ventricular Dysfunction, Left / Q000000981:diagnostic imaging / Q000473:pathology*
chemical_list: D000959:Antihypertensive Agents; D007166:Immunosuppressive Agents